Wall Street analyst estimates for Viatris Inc. (VTRS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs).
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 8 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 13 |
| Avg rating (1-5) | 0.23 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $0.65 | ||
| 2026-08-06 | $0.69 | $0.60 | +14.8% |
| 2026-05-07 | $0.59 | $0.50 | +17.5% |
| 2026-02-26 | $0.57 | $0.53 | +7.1% |
| 2025-11-06 | $0.67 | $0.62 | +7.9% |
| 2025-08-07 | $0.62 | $0.56 | +11.5% |
| 2025-05-08 | $0.50 | $0.49 | +1.6% |
| 2025-02-27 | $0.54 | $0.61 | -11.5% |
Valuation Ratios
| Price / Book | 1.44 |
| EV / EBITDA | -70.63 |
| Dividend Yield | 2.73% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.08B | $11.91B | $11.43B | $11.50B | $11.95B | $17.89B | $16.26B | $15.43B | $14.74B | $14.30B |
| Cost of Revenue | $6.38B | $7.12B | $7.43B | $7.60B | $8.15B | $12.31B | $9.77B | $8.99B | $9.12B | $9.29B |
| Gross Profit | $4.70B | $4.78B | $4.00B | $3.90B | $3.80B | $5.58B | $6.50B | $6.44B | $5.62B | $5.01B |
| Research & Development | $826.8M | $783.3M | $704.5M | $639.9M | $512.6M | $681.0M | $662.2M | $805.2M | $808.7M | $965.9M |
| Selling, General & Admin | $2.50B | $2.58B | $2.44B | $2.56B | $3.34B | $4.53B | $4.18B | $4.65B | $4.43B | $3.79B |
| Operating Expenses | $4.00B | $3.35B | $3.10B | $3.18B | $4.01B | $5.61B | $4.88B | $5.67B | $5.61B | $7.68B |
| Operating Income | $699.2M | $1.44B | $905.6M | $715.5M | -$210.8M | -$34.0M | $1.61B | $766.2M | $10.1M | -$2.66B |
| EBITDA | $2.10B | $3.24B | $2.95B | $2.69B | $1.99B | $4.48B | $6.43B | $3.52B | $2.82B | -$395.4M |
| Interest Expense | $454.8M | $534.6M | $542.3M | $517.3M | $497.8M | $636.2M | $592.4M | $573.1M | $550.0M | $471.3M |
| Pre-tax Income | $121.7M | $903.0M | $298.4M | $154.4M | -$721.2M | -$664.4M | $2.81B | $202.9M | -$623.2M | -$3.67B |
| Income Tax | -$358.3M | $207.0M | -$54.1M | $137.6M | -$51.3M | $604.7M | $734.6M | $148.2M | $11.0M | -$150.1M |
| Net Income | $480.0M | $696.0M | $352.5M | $16.8M | -$669.9M | -$1.27B | $2.08B | $54.7M | -$634.2M | -$3.51B |
| EPS | $0.94 | $1.30 | $0.69 | $0.03 | $-1.11 | $-1.05 | $1.71 | $0.05 | $-0.53 | $-3.00 |
| EPS (Diluted) | $0.92 | $1.30 | $0.68 | $0.03 | $-1.11 | $-1.05 | $1.71 | $0.05 | $-0.53 | $-3.00 |
| Shares Outstanding (Diluted) | $520.5M | $536.7M | $516.5M | $516.5M | $601.2M | $1.21B | $1.22B | $1.21B | $1.19B | $1.17B |
Price
| Price | $17.60 |
| Market Cap | $20.5B |
| Exchange | NASDAQ |
| Country | US |
Related companies: BAX · BBIO · ELAN · EXAS · IONS · MRNA · NBIX
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of VTRS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks